Compare · ALMR vs WAT
ALMR vs WAT
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $37.66B, about 26.6x ALMR ($1.42B).
- Over the past year, ALMR is down 7.6% and WAT is up 11.7% - WAT leads by 19.3 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- WAT has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Waters Corporation
- Price
- $20.50+3.90%
- $384.00+4.71%
- Market cap
- $1.42B
- $37.66B
- 1M return
- -16.29%
- +31.47%
- 1Y return
- -7.64%
- +11.70%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 1995
- News (4w)
- 5
- 5
- Recent ratings
- 5
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest ALMR
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
- Leerink Partners initiated coverage on Alamar Biosciences with a new price target
- Stifel initiated coverage on Alamar Biosciences with a new price target
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports First Quarter 2026 Financial Results
- Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
- Alamar Biosciences to Report First Quarter 2026 Financial Results on May 8, 2026
Latest WAT
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Waters Corporation
- Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
- Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules